ArticleFEBS open bio2017
Licochalcone A specifically induces cell death in glioma stem cells via mitochondrial dysfunction.
Article in FEBS open bio, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Anticancer effects of licochalcones: A review of the mechanisms.Frontiers in pharmacology · 2023Pooled it
- Licochalcone a Disrupted Mitochondrial Function to Promote Cuproptosis in Glioblastoma Through Regulating RAS/MAPK Pathway.Applied biochemistry and biotechnology · 2026Article
- Recent Advances in the Synthesis and Biological Applications of Prenylated Chalcones.International journal of molecular sciences · 2025Review
- Targeting the Mitochondria in High-Grade Gliomas.Cancers · 2025Review
- HDAC Class I Inhibitor Domatinostat Induces Apoptosis Preferentially in Glioma Stem Cells Through p53-Dependent and -Independent Activation of BAX Expression.International journal of molecular sciences · 2025Article
- Targeting Mitochondria in Glioma: New Hopes for a Cure.Biomedicines · 2024Review
- The MDM2-p53 Axis Represents a Therapeutic Vulnerability Unique to Glioma Stem Cells.International journal of molecular sciences · 2024Article
- Licochalcone A: a review of its pharmacology activities and molecular mechanisms.Frontiers in pharmacology · 2024Review
- HDAC Class I Inhibitor Domatinostat Preferentially Targets Glioma Stem Cells over Their Differentiated Progeny.International journal of molecular sciences · 2022Article
- Targeting Mitochondrial Oxidative Phosphorylation in Glioblastoma Therapy.Neuromolecular medicine · 2022Review
- Network pharmacological analysis of active components of Xiaoliu decoction in the treatment of glioblastoma multiforme.Frontiers in genetics · 2022Article
- Role of Licochalcone A in Potential Pharmacological Therapy: A Review.Frontiers in pharmacology · 2022Review
- Licochalcone A activation of glycolysis pathway has an anti-aging effect on human adipose stem cells.Aging · 2021Article
- Targeting Folate Metabolism Is Selectively Cytotoxic to Glioma Stem Cells and Effectively Cooperates with Differentiation Therapy to Eliminate Tumor-Initiating Cells in Glioma Xenografts.International journal of molecular sciences · 2021Article
- Article
- Natural Chalcones in Chinese Materia Medica: Licorice.Evidence-based complementary and alternative medicine : eCAM · 2020Review
- Licochalcone A Suppresses the Proliferation of Osteosarcoma Cells through Autophagy and ATM-Chk2 Activation.Molecules (Basel, Switzerland) · 2019Article
- Antibacterial Effect and Mode of Action of Flavonoids From Licorice Against Methicillin-ResistantFrontiers in microbiology · 2019Article
- Repositioning CEP-1347, a chemical agent originally developed for the treatment of Parkinson's disease, as an anti-cancer stem cell drug.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma multiforme is the most malignant primary intrinsic brain tumor. Glioma stem cells (GSCs) are associated with chemoradiotherapy resistance and the recurrence of glioblastomas after conventional therapy. The targeting of GSCs is potentially an effective treatment for the long-term survival of glioblastoma patients. Licochalcone A, a natural chalconoid from licorice root, exerts anticancer effects; however, its effect on GSCs remains unknown. We found that Licochalcone A induced massive caspase-dependent death in GSCs but not in differentiated GSCs nor normal somatic and neural stem cells. Prior to cell death, Licochalcone A caused mitochondrial fragmentation and reduced the membrane potential and ATP production in GSCs. Thus, Licochalcone A induces mitochondrial dysfunction and shows promise as an anticancer stem cell drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.